BioSpace News Archive

The U.S. Food and Drug Administration published guidance that will help provide a pathway for infant formulas operating under enforcement discretion in the U.S. to remain on the market.

A first-of-its-kind study published in AACC’s Clinical Chemistry journal shows that a novel drug test detects a new class of synthetic cannabinoids called OXIZIDs.

Zealand Pharma A/S, a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.

Clene Inc. along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, announced that it will report topline results of the CNM-Au8® regimen of the HEALEY ALS Platform Trial on Monday, Oct. 3.

Pyxis Oncology, Inc. reported on September 30, 2022 that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 213,030 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 266,290 shares of Pyxis Oncology’s common stock to seventeen newly hired employees.

Apellis Pharmaceuticals, Inc. announced new data from the 24-month Phase 3 OAKS study of pegcetacoplan, an investigational targeted C3 therapy, for the treatment of geographic atrophy secondary to age-related macular degeneration.

Adicet Bio, Inc. announced it granted inducement awards on September 30, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to four individuals hired by Adicet in September 2022.

Aptorum Group Limited provided a business update and announced financial results for the six months ended June 30, 2022.